The acquisition closes a multi-year strategic option and adds a FDA-approved platform technology to Artivion's aortic arch portfolio. Monitor the next 2-3 quarters for initial Nexus revenue contribution and any updates on the contingent consideration earn-out trajectory. The $150 million term loan increases leverage, so watch for debt paydown plans or refinancing.
Price Chart
Executive Summary
Artivion completed its acquisition of Endospan Ltd. on May 18, 2026, exercising a long-standing option to purchase all outstanding securities. The net purchase price was approximately $131.3 million in cash, funded via a $150 million delayed draw term loan, with an additional $16.5 million placed in an indemnity escrow and $1.0 million in an adjustment escrow. Sellers are also eligible for up to $200 million in contingent consideration based on future Nexus product performance, payable approximately two years post-closing. The FDA approved the Nexus system's PMA in April 2026, and Artivion now holds a complete aortic arch portfolio.
Key Facts
- Artivion completed the acquisition of Endospan Ltd. on May 18, 2026.
- Net purchase price of approximately $131.3 million paid in cash by CryoLife Asia Pacific Pte. Ltd.
- Funded via a previously drawn $150 million delayed draw term loan.
- $16.5 million deposited into an indemnity escrow fund and $1.0 million into an adjustment escrow fund.
- Sellers eligible for up to $200 million in contingent consideration based on future Nexus product performance, payable ~2 years post-closing.
- FDA approved the Nexus Aortic Arch Stent Graft System PMA in April 2026.
- Artivion now has a complete three-pronged aortic arch portfolio (NEXUS, AMDS, ARCEVO LSA).
Financial Impact
Net cash outlay of ~$131.3 million, funded by a $150 million delayed draw term loan. Up to $200 million in potential contingent consideration.
Risk Factors
- Integration risk of Endospan's operations and technology.
- Commercial adoption of the Nexus system may be slower than expected.
- Contingent consideration of up to $200 million could pressure cash flow if Nexus revenue targets are met.
- Increased leverage from the $150 million term loan.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-035798 |
| Document: aort-2026x8k03312026ex102.htm | 0001628280-26-035798 |
| Document: aort-20260518.htm | 0001628280-26-035798 |
| Document: aort-2026x8k03312026ex103.htm | 0001628280-26-035798 |
| Document: aort-2026x8k051826ex991.htm | 0001628280-26-035798 |
| Document: 0001628280-26-035798-index-headers.html | 0001628280-26-035798 |
| Document: 0001628280-26-035798-index.html | 0001628280-26-035798 |
| Document: 0001628280-26-035798.txt | 0001628280-26-035798 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $22.98 | awaiting T+60 | — | $22.98 (−0.00%) |
Aug 20, 2026 9w ago | Insider Cluster | $27.98 | awaiting T+60 | — | $22.98 (−17.87%) |
May 18, 2026 23w ago | 8-K | $23.76 $28.64 | ▲ +20.54% | ▲ +15.69% | $22.98 (−3.28%) |
Apr 1, 2026 29w ago | DEFA14A | $34.17 $22.47 | ▼ −34.24% | ▼ −48.40% | $22.98 (−32.75%) |
Mar 2, 2026 34w ago | Insider Cluster | $38.55 $23.19 | ▲ +39.84% | ▲ +49.17% | $22.98 (+40.39%) |
Feb 24, 2026 35w ago | Insider Cluster | $35.35 $22.73 | ▼ −35.70% | ▼ −42.45% | $22.98 (−34.99%) |
Feb 23, 2026 35w ago | Insider Cluster | $37.39 $23.76 | ▲ +36.45% | ▲ +44.71% | $22.98 (+38.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers